Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Tempus AI, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$75.92-4.4%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed November 2, 2026
Tempus sells genetic tests ordered by doctors for cancer patients, with insurers or patients paying, and licenses health data to drug companies.
Company outlook: revenue of $1.6B to $1.6B for Fiscal year 2026 — up 26.0% on a year earlier